Known symptomatic brain metastases
Patient has symptomatic brain metastases (i.e., metastases that are accompanied by neurological symptoms or that require treatment with corticosteroids)
Brain metastases requiring steroids
Known symptomatic brain metastases requiring ? mg/day of prednisolone (or its equivalent).
Patients with known symptomatic brain metastases requiring steroids in part  or 
Symptomatic or uncontrolled brain metastases
Patients with brain metastases will be excluded if metastases have been symptomatic or actively treated within  weeks prior to enrollment
Symptomatic or clinically active brain metastases
Has clinically active brain metastases, defined as untreated and symptomatic, or requiring therapy with steroids or anticonvulsants to control associated symptoms (participants with treated brain metastases that are no longer symptomatic and who require no treatment with steroids may be included in the study if they have recovered from the acute toxic effect of radiotherapy)
Patients with known symptomatic brain metastases requiring steroids
Presence of symptomatic brain metastases or brain metastases requiring escalating doses of corticosteroids to control neurological symptoms
Symptomatic or unstable brain metastases.
Patients with symptomatic extrahepatic metastases
Symptomatic brain metastases
Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.
Symptomatic brain metastases
Symptomatic brain metastases
Known symptomatic brain metastases requiring steroids.
Patients with symptomatic brain metastases are excluded from this study
Symptomatic or uncontrolled brain metastases;
Patients with known symptomatic brain metastases requiring steroids.
Symptomatic or progressive brain metastases.
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
Patients with symptomatic brain metastases.
Symptomatic uncontrolled brain metastases
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
Participants with symptomatic or growing brain metastases less than  weeks prior to enrollment.
Presence of symptomatic brain metastases requiring immediate treatment with radiation therapy or steroids.
The participant has brain metastases that are symptomatic.
Symptomatic brain metastases or brain metastases requiring chronic steroids to control symptoms.
Brain metastases requiring steroids
Patients with known brain metastases requiring steroids.
Participants with symptomatic or progressive brain metastases, or requiring steroids to control symptoms of brain metastases
Known untreated, symptomatic, or progressive brain metastases; presence of carcinomatous meningitis; history of intracranial hemorrhage; or brain metastases requiring chronic steroids
Symptomatic or clinically active brain metastases
Symptomatic brain metastases (prior treatment and stable metastases are allowed)
Subjects with symptomatic uncontrolled brain metastases;
Patients with known active or symptomatic brain metastases prior to vaccination.
Patients with known symptomatic brain metastases requiring steroids.
Symptomatic brain metastases.
Symptomatic brain metastases
Symptomatic brain metastases
Symptomatic brain metastases.
Symptomatic brain metastases.
Brain metastases requiring steroids
Brain metastases requiring steroids.
Symptomatic brain metastases
Patient has symptomatic brain metastases, ie, presence of neurological symptoms or requiring treatment with corticosteroids, or CNS leukemia.
Any known symptomatic brain metastases requiring steroids.
Patient with brain metastases that are symptomatic and/or require therapy.
Patients with known symptomatic brain metastases requiring steroids
Brain metastases requiring steroids
Symptomatic and progressive or corticosteroid-requiring documented brain metastases
Presence of symptomatic brain metastases at time of study consent process; patients with history of treated brain metastases are eligible if they are not symptomatic at the time of study enrollment
Patients with history of epilepsy, brain damage, or symptomatic brain metastases.
Participants with symptomatic uncontrolled brain metastases; a scan to confirm the absence of brain metastases is not required
Patients with symptomatic brain metastases are excluded from this study.
Participants must not have symptomatic brain metastases or brain metastases requiring steroids; asymptomatic brain metastases not requiring steroids are acceptable
Symptomatic brain metastases
